1,266 reports of this reaction
6.3% of all POSACONAZOLE DELAYED RELEASE reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for POSACONAZOLE DELAYED RELEASE, manufactured by A2A Integrated Pharmaceuticals. There are 1,266 FDA adverse event reports linking POSACONAZOLE DELAYED RELEASE to DRUG INEFFECTIVE. This represents approximately 6.3% of all 20,089 adverse event reports for this drug.
Patients taking POSACONAZOLE DELAYED RELEASE who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among POSACONAZOLE DELAYED RELEASE users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for POSACONAZOLE DELAYED RELEASE:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 1,266 FDA reports for POSACONAZOLE DELAYED RELEASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 6.3% of all adverse event reports for POSACONAZOLE DELAYED RELEASE, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking POSACONAZOLE DELAYED RELEASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.